Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Condition:   Breast Cancer Intervention:   Drug: Talazoparib Sponsors:   Massachusetts General Hospital;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 20 July 2019Source: European Journal of Surgical OncologyAuthor(s): Nikhil Panda, Ian Solsky, Alex B. HaynesAbstractPerioperative shared decision-making can be improved through the development of novel patient-centered outcome measures made possible by digital phenotyping—“the moment-by-moment quantification of individual-level human phenotype in situ using data from personal digital devices, in particular smartphones.” This Short Report presents data from a patient with breast cancer that illustrates the opportunities of digital phenotyping to better inform patient qual...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This article reviews targeted therapy treatment options for patients with metastatic BC, including strategies for administration, side effects, and nursing considerations. PMID: 31322617 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin J Oncol Nurs Source Type: research
Authors: Kongsema M, Wongkhieo S, Khongkow M, Lam EW, Boonnoy P, Vongsangnak W, Wong-Ekkabut J Abstract Breast cancer is the most common type of malignancies in women worldwide, and genotoxic chemotherapeutic drugs are effective by causing DNA damage in cancer cells. However,>90% of patients with metastatic cancer are resistant to chemotherapy. The Forkhead box M1 (FOXM1) transcription factor plays a pivotal role in the resistance of breast cancer cells to chemotherapy by promoting DNA damage repair following genotoxic drug treatment. The aim of the present study was to investigate the inhibition of the FOXM1 pr...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In conclusion, PARP1/2 inhibitors decrease the ubiquitination of ALC1 leading to the accumulation of ALC1, which affects the therapeutic effects of DNA damage response drugs in breast cancer treatment. PMID: 31322269 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Protein kinase A activation by β‑Lapachone is associated with apoptotic cell death in NQO1‑overexpressing breast cancer cells. Oncol Rep. 2019 Jul 19;: Authors: Zada S, Hwang JS, Ahmed M, Lai TH, Pham TM, Kim DH, Kim DR Abstract One million females are diagnosed worldwide every year with breast cancer, and the mortality rate of these patients remains high. Several treatments, including surgery, are available for breast cancer. β‑Lapachone (β‑Lap), a natural quinone compound, has been developed for cancer treatment due to its strong cytotoxic effect through its action on NAD(P)H:q...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Zsóková E, Ilkovičová L, Kimáková P, Fecková B, Solár P Abstract While erythropoietin (EPO) regulates erythropoiesis, the erythropoietin receptor (EPOR) has been identified in many non‑hematopoietic cells, including cancer. Our previous study demonstrated that overexpression of EPOR altered the cell growth and the sensitivity of RAMA 37 breast cancer cells to tamoxifen. Indeed, results of the present study uncovered the role of EPOR in the resistance of EPOR‑overexpressing RAMA 37‑28 cells to paclitaxel chemotherapy. In this regard, EPOR silencing in ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Evaluation of the STAT3 inhibitor GLG‑302 for the prevention of estrogen receptor‑positive and ‑negative mammary cancers. Oncol Rep. 2019 Jul 04;: Authors: Shoemaker RH, Fox JT, Juliana MM, Moeinpour FL, Grubbs CJ Abstract Signal transducer and activator of transcription 3 (STAT3) plays a key role in the transformation of normal cells to cancerous cells. Although inhibitors of STAT3 have been shown to suppress the growth of multiple cancer types in vitro and in vivo, such agents are of particular interest for the prevention of breast cancer, which affects over 200,000 women an...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Wang Y, Song Z, Leng P, Liu Y Abstract Serum deprivation response (SDPR) gene has been recently characterized as a gene signature marker or serving a tumor suppressor role in specific types of cancer. However, gene expression alterations of SDPR in various types of cancer and their relevance to clinical outcomes remain unclear. In the present study, SDPR expression was profiled using the Oncomine database, and SDPR downregulation was indicated in most types of cancer. In agreement with previously reported breast cancer cases, downregulation of SDPR was indicated to be significantly associated with poor sur...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Conclusion: Genomic discordance of paired primary and metastatic TNBCs was identified, with significant increase in tumor proliferation pathways seen in metastases. Among the differentially expressed genes, AKT3 can potentially serve as a target for novel combination therapy for treatment of metastatic TNBC. Methods: Paired specimens from 10 patients with TNBCs were identified through an IRB-approved protocol (2002-2015). FoundationOneTM sequencing was performed for genomic profiling, and Affymetrix Human Genechip 2.0st was used for mRNA expression profiling. The similarity among samples was calculated based on Pearson cor...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Gilmore E, McCabe N, Kennedy RD, Parkes EE Abstract Historically the development of anticancer treatments has been focused on their effect on tumor cells alone. However, newer treatments have shifted attention to targets on immune cells, resulting in dramatic responses. The effect of DNA repair deficiency on the microenvironment remains an area of key interest. Moreover, established therapies such as DNA damaging treatments such as chemotherapy and PARP inhibitors further modify the tumor microenvironment. Here we describe DNA repair pathways in breast cancer and activation of innate immune pathways in DNA...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Hospitals | Pfizer | Research